Clinical Trials Logo

Filter by:
NCT ID: NCT05905614 Completed - Clinical trials for Advanced Solid Tumors

Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid Tumors

Start date: November 3, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This clinical study evaluated the safety and efficacy of SPH4336 in the treatment of advanced solid tumors.

NCT ID: NCT05905588 Recruiting - Type 2 Diabetes Clinical Trials

Study of Hydrogen-rich Water Compared With Placebo in Type 2 Diabetes Patients

Start date: March 1, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of hydrogen-rich water in type 2 diabetes patients.

NCT ID: NCT05905458 Active, not recruiting - Chronic Hepatitis B Clinical Trials

A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs)

Start date: July 28, 2023
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of HRS9950 tablets in chronic hepatitis B patients who are virologically suppressed on nucleoside or nucleotide analogues (NAs).

NCT ID: NCT05905354 Recruiting - HSIL of Cervix Clinical Trials

Clinical Study of HPV Therapeutic DNA Vaccine (NWRD08) in Patients With Cervical HPV16 and/or HPV18 Positive

Start date: March 7, 2022
Phase: N/A
Study type: Interventional

This is an open-label exploratory clinical study. The main objective is to explore the immunogenicity of HPV therapeutic DNA vaccine NWRD08.

NCT ID: NCT05905198 Recruiting - Parkinson's Disease Clinical Trials

Programming Strategy of VFS for Gait Impairments in PD

Start date: May 24, 2023
Phase: N/A
Study type: Interventional

Variable Frequency Stimulation(VFS) is a stimulation pattern applied in Deep Brain Stimulation(DBS) therapy for Parkinson's disease(PD). Peking Union Medical College Hospital was the first centre conducting research on VFS. The studies in the past have resembled conclusion that VFS provides improvement not only in the major symptoms such as tremor and rigidity, but also in gait and balance disorder. However, the best programming strategy of VFS has not met agreement. The random-controlled double blinded crossover study is designed for participants who underwent DBS surgery in bilateral subthalamic nucleus for parkinson's disease. The investigators study several strategies on programming and observe the improvement of symptom to look for the best one. A 4-month follow-up is designed to observe a relatively long-term effectiveness of VFS. The study intends to gather more clinical evidence to guide further studies on VFS application.

NCT ID: NCT05905172 Recruiting - Liver Fibrosis Clinical Trials

Hydroxynidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis

Start date: August 12, 2023
Phase: Phase 3
Study type: Interventional

This study is a Phase IIIb extension trial following the "randomized, double-blind, placebo-controlled, entecavir basic treatment, multi-center Phase III clinical trial of hydroxnidone capsules in the treatment of liver fibrosis of chronic viral hepatitis B". The main objective of this study is to evaluate the effectiveness and the safety of hydroxyeidone capsules for long-term treatment of patients with chronic viral hepatitis B liver fibrosis.

NCT ID: NCT05905133 Active, not recruiting - Atopic Dermatitis Clinical Trials

A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe AD

Start date: July 15, 2023
Phase: Phase 2
Study type: Interventional

This study is a single-arm, open-label, multi-center clinical study designed to assess the safety and efficacy of CBP-201 in eligible subjects with moderate to severe Atopic Dermatitis.

NCT ID: NCT05905120 Completed - Clinical trials for Major Depressive Disorder

Assessing Dopamine Transporter Occupancy in the Healthy Adult Brain With Toludivenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)

Start date: March 2, 2023
Phase: Phase 1
Study type: Interventional

This study was a single-arm, non-randomized, open-label clinical study to assess dopamine transporter occupancy in the brain of healthy adults using 11C-CFT positron emission tomography (PET)

NCT ID: NCT05905003 Recruiting - Psychosis Clinical Trials

AMP SCZ® Observational Study: PREDICT-DPACC

AMP SCZ
Start date: June 2, 2022
Phase:
Study type: Observational

The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) is a large international collaboration to develop algorithms using a set of clinical and cognitive assessments, multi-modal biomarkers, and clinical endpoints that can be used to predict the trajectories and outcomes of individuals at clinical high risk (CHR) for psychosis and to advance the testing of pharmacological interventions for CHR individuals in need. The goal is to accurately predict which individuals are likely to remit, experience an acute psychotic episode, or have intermediate outcomes that feature persistent attenuated psychotic and/or mood symptoms along with functional impairment. The prediction algorithms will have the potential to serve as early indicators of treatment efficacy in CHR persons. The AMP SCZ research program is made up of the Psychosis Risk Evaluation, Data Integration, and Computational Technologies - Data Processing, Analysis and Coordination Center (PREDICT-DPACC) and two clinical research networks, the Psychosis-Risk Outcomes Network (ProNET) and the Trajectories and Predictors in the Clinical High Risk for Psychosis Population: Prediction Scientific Global Consortium (PRESCIENT) networks. The two clinical research networks will recruit a large cohort of CHR young people aged 12-30 years (n=1,977) and healthy control (HC) participants (n=640) across 42 participating investigative sites from 13 countries. CHR participants will complete screening, baseline assessments and a battery of follow-up assessments across 18 - 24 months. HC participants will complete screening and baseline assessments and a subset (5 per site) will complete month 2, 12 and 24 visits.

NCT ID: NCT05904977 Recruiting - Cervical Cancer Clinical Trials

Preliminary Study on the Metastatic Rate and Clinical Significance of the Anterior Leaf of Vesicouterine Ligament in Early Stage Cervical Cancer

Start date: April 1, 2019
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to preliminarily explore the metastatic rate and clinical significance of the anterior leaf of vesicouterine ligament resection for early stage cervical cancer, so as to further improve the postoperative quality of life of patients and reduce the incidence of postoperative urinary complications.